Peroxisome proliferator-activated receptor-g (PPARg) is a transcription factor that regulates lipid metabolism and inflammatory responses. Certain PPARg ligands improve nonalcoholic steatohepatitis (NASH). The role of PPARg itself in NASH remains poorly understood. The functional consequences of PPARg in the development of steatohepatitis through gene deficiency or gene overexpression of PPARg delivered by adenovirus (Ad-PPARg) were examined. Our results show that PPARg-deficient (PPARg +/À ) mice fed the methionine-and choline-deficient (MCD) diet developed more severe steatohepatitis than wild-type mice, and were unaffected by PPARg ligand rosiglitazone. Overexpression of PPARg delivered by Ad-PPARg attenuated steatohepatitis. This effect was associated with redistribution of fatty acid from liver to adipose tissue by enhancing expression of fatty acid uptake genes (fatty acid binding protein-4 (aP2), fatty acid translocase (CD36), lipoprotein lipase (LPL) and fatty acid transport protein-1 (FATP-1) ) and lipogenic genes (sterol regulatory element binding protein isoform-1 (SREBP-1) and stearoyl-CoA desaturase isoform-1 (SCD-1)) in adipose tissue and to a lesser extent in liver. The anti-steatohepatitis action of PPARg was also mediated via regulating adipokines through suppressing tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) and inducing adiponectin. Moreover, PPARg activation suppressed hepatic lipoperoxide and reduced hepatic pro-inflammatory cytokines (TNF-a and IL-6) production. In conclusion, PPARg is an important endogenous regulator and potential therapeutic target for nutritional steatohepatitis.
Introduction
Nonalcoholic steatohepatitis (NASH) is an advanced stage of nonalcoholic fatty liver disease characterized by accumulation of hepatic fat, inflammation and with or without fibrosis. Peroxisome proliferator-activated receptor-g (PPARg) is a transcriptional regulator that modulates adipocyte differentiation, fat metabolism and inflammation. 1, 2 The efficacy of PPARg ligands as potential anti-NASH therapies has been explored and found to improve glucose and lipid metabolism in type II diabetes, ameliorate hepatic inflammation and accumulate fat in steatohepatitis. 3, 4 However, the treatment response of PPARg ligands is highly variable and difficult to predict, and the mechanisms underlying the response or non-responsiveness of this treatment is largely unknown. 3, 4 Moreover, a major limitation of the studies in both human 3, 4 or animal NASH 5 is that only PPARg ligands were used to evaluate the role of PPARg. As PPARg ligands have a variety of PPARg-independent effects, the role of PPARg in the evolution of NASH remains unclear. PPARg modulation using a genetic approach may help to understand the mechanisms underlying the response or non-responsiveness of this treatment and may help to overcome potential resistance mechanisms. In this study, the potential effects of PPARg in nutritional steatohepatitis in mice with gain or loss of function of PPARg were analyzed.
Results

Increased susceptibility of PPARg-deficient (PPARg +/À ) mice with MCD-induced steatohepatitis
Relative to wild-type littermates, PPARg +/À mice had more pronounced steatosis and inflammation after being challenged with methionine-and choline-deficient (MCD) diet for 4 weeks ( Figure 1a and Table 1 ). Consistent with the severe steatohepatitis in PPARg +/À mice fed the MCD diet, serum alanine aminotransferase (ALT), intrahepatic triglyceride (TG) and lipoperoxide levels were significantly higher than those of MCD dietfed wild-type mice (Figure 1b) . PPARg +/À mice fed control diet had normal liver histology ( Figure 1a and Table 1 ) and ALT level (43±7). 
Introduction of PPARg by gene delivery counteracted the development of steatohepatitis
As genetic deficiency of PPARg developed pronounced steatohepatitis and had poor therapeutic response to PPARg ligands, whether the introduction of PPARg through gene delivery could alter the development of steatohepatitis was tested. Wild-type mice fed the MCD or control diet were administered adenovirus (Ad)-PPARg (2.5 Â 10 8 plaque-forming units (PFU)) or AdLacZ (2.5 Â 10 8 PFU) (as control) for up to 4 weeks. Overexpression of PPARg was confirmed in Ad-PPARgtransfected mice in both liver and white adipose tissue (WAT) using western blot assays (Figure 2 ). The introduction of Ad-PPARg in mice fed the MCD diet significantly attenuated hepatic steatosis and inflammation ( Figure 3a and Table 2 ) compared with mice fed the MCD diet administered Ad-LacZ. Serum ALT and hepatic TGs were also significantly reduced (Figure 3b ).
In contrast, the administration of Ad-LacZ or Ad-PPARg in mice fed the control diet had no effect on the liver histology ( Figure 3a and Table 3 ).
Introduction of PPARg gene combining with rosiglitazone showed a better effect in the prevention of steatohepatitis
In view of the observed incomplete anti-steatosis and anti-inflammatory effects of rosiglitazone or Ad-PPARg in mice fed the MCD diet, it was therefore of considerable interest to study whether the combination of AdPPARg and its ligand rosiglitazone may exert a better effect to abrogate the development of MCD dietary steatohepatitis. MCD-feeding mice treated with AdPPARg plus rosiglitazone 150 p.p.m. achieved almost complete remission (Figures 3a and b , and Table 2 ).
Combination of Ad-PPARg and rosiglitazone fully reversed MCD diet-induced steatohepatitis After confirming a clear preventive effect of steatohepatitis, whether Ad-PPARg plus rosiglitazone could ameliorate the severity of the liver histology in established steatohepatitis was further assessed. After induction of steatohepatitis in mice fed the MCD diet for 3 weeks, 6 rosiglitazone with or without Ad-PPARg was supplemented for 2 weeks under MCD diet. Administration of rosiglitazone was associated with partial but significant reduction in serum ALT levels, hepatic TG and lipoperoxide levels ( Table 3 ). The severity of liver histology was also reduced, several large lipid droplets remained but inflammatory foci were reduced in size ( Figure 4 ) compared with untreated MCD diet-fed mice. In mice treated with rosiglitazone plus Ad-PPARg, very few small fat droplets remained and inflammatory cells were almost completely absent (Figure 4 ). Histological grading of liver sections and serum chemistry confirmed the significant improvement of hepatic injury achieved by rosiglitazone plus Ad-PPARg treatment ( Table 3) .
Inhibition of cytokines TNF-a and IL-6 expression in the liver by Ad-PPARg gene modulation
To elucidate the mechanisms of the effect of Ad-PPARg on steatohepatitis, hepatic levels of pro-inflammatory cytokines, including tumor necrosis factor-a (TNF-a), interleukin (IL)-6, IL-1b and interferon-g, were analyzed. Gene delivery by Ad-PPARg to MCD-fed mice led to significant decrease of TNF-a (1.00±0.17 vs 0.62±0.19, Po0.05) and IL-6 (1.00 ± 0.20 vs 0.59 ± 0.17, Po0.05) when compared with Ad-LacZ-treated mice fed the MCD diet. However, the levels of interferon-g and IL-1b were not significantly changed.
Effects of PPARg on the expression of genes involved in fatty acid regulation in both liver and WAT
To seek an explanation for the hepatic TG-lowering effects of PPARg, mRNA levels of PPARg-mediated fatty acid uptake genes including aP2 (fatty acid binding protein-4), FATP-1 (fatty acid transport protein-1), CD36, LPL (lipoprotein lipase) and acyl CoA synthase, and lipogenic genes including SREBP-1 (sterol regulatory element binding protein isoform-1) and its downstream gene SCD-1 (stearoyl-CoA desaturase isoform-1), were assessed in both liver and WAT. As shown in Table 4 , administration of Ad-PPARg significantly increased (Table 4 ). In contrast, Ad-PPARg together with rosiglitazone only increased SCD-1 (sevenfold) and SREBP-1 (threefold) mRNA in liver. Thus, the fatty acid synthesis was much more vigorous in WAT than in liver under treatment of Ad-PPARg, especially combining Ad-PPARg with rosiglitazone.
Effects of PPARg on adipokines expression in WAT
Anti-inflammatory adipokine (adiponectin) and proinflammatory adipokines (TNF-a and IL-6) in WAT were analyzed. In mice treated with Ad-PPARg, there was increased protein expression of adiponectin. Furthermore, there was a more significant increase in expression of adiponectin observed in mice treated with Ad-PPARg plus rosiglitazone (Figure 5b ). In addition, TNF-a ( Figure 5c ) and IL-6 ( Figure 5d ) mRNA in WAT were restored to normal levels under this combining treatment.
Effects of Ad-PPARg or Ad-PPARg plus rosiglitazone on body weight of mice fed the MCD diet
Mice on the MCD diet for 4 weeks had a body weight reduction of 35% when compared with mice on control diet. MCD-fed mice administered Ad-PPARg had a body weight 5% higher than MCD-fed mice untreated with Ad-PPARg (Po0.01). This effect was more prominent in the mice given both Ad-PPARg and rosiglitazone, (150 p.p.m.) which had a 10% higher body weight compared with the untreated MCD group (Po0.001; Figure 5a ).
Discussion
This study showed that the deficiency of endogenous PPARg in PPARg +/À mice fed the MCD diet resulted in steatohepatitis significantly more severe than their wildtype counterparts; conferring endogenous PPARg negatively regulated accumulation of intrahepatic lipids and protected against steatohepatitis. Moreover, rosiglitazone improved liver injury in wild-type mice. PPARg +/À mice fed the MCD diet were refractory to rosiglitazone treatment. This further supports the existence of an endogenous PPARg pathway that exerted an antisteatohepatitis role. Together, these observations encouraged us to define the utility of increasing endogenous PPARg levels during progression of steatohepatitis through adenovirus-mediated gene therapy. Indeed, adenovirus-mediated PPARg gene therapy resulted in 
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CW Wu et al preventive benefit in the MCD-induced steatohepatitis model. Rosiglitazone is a synthetic ligand for PPARg that participates in regulating fat metabolism, energy homeostasis and inflammation. After ligand binding to the PPARg, the PPARg-ligand complex forms a heterodimer with the retinoid X receptor, which binds to the response element of specific target genes to stimulate transcription. PPARg +/À mice have diminished ligand-binding and DNA-binding functions. 7 Thus, quantification of PPARg may be necessary for therapeutic effectiveness of rosiglitazone through activation of this endogenous pathway. In this regard, the effect of combination of Ad-PPARg with rosiglitazone in steatohepatitis was assessed to better define whether this combination shows a better anti-steatohepatitic property. In the present work, mice treated with Ad-PPARg plus rosiglitazone showed dramatic improvements in prevention and regression of steatohepatitis, suggesting a beneficial effect of overexpression of PPARg and rosiglitazone on this disorder. In addition, administration of Ad-PPARg alone also achieved partial therapeutic effects in the prevention of steatohepatitis, indicating that restoration of PPARg levels during steatohepatitis might allow for interactions with endogenous ligands that activated the anti-steatosis/anti-inflammatory program. These observations also suggested that diminished PPARg in humans with NASH might be refractory to PPARg ligand treatment.
The mechanisms involved in the therapeutic effects of PPARg in steatohepatitis were analyzed. PPARg promotes fatty acid storage and uptake in adipose tissue through regulating a number of fatty acid uptake and adipogenesis genes in adipose tissue. 8, 9 Although the effect of Ad-PPARg or its ligands on liver fat content has been documented in previous animal studies, 10, 11 their effect on adipose tissue was not included. The pattern of genes expressed in WAT and liver as a result of PPARg overexpression was defined. Our results indicated that introduction of PPARg in mice resulted in a markedly upregulated uptake of fatty acid genes (FATP-1, aP2 and CD36) and adipogenesis genes (SREBP-1 and SCD-1) in WAT. A further enhanced expression of these genes together with upregulation of LPL was shown in WAT in mice treated with Ad-PPARg plus rosiglitazone. It is well recognized that FATP-1, LPL, CD36 and aP2 are lipoprotein receptor/fatty acid transporters and involved in fatty acid uptake. They have major roles in enhancing the redistribution of fat from other tissues including liver to WAT.
12,13 SREBP-1 has a key role in lipogenesis in the adipose cell, which activates genes required for fatty acid synthesis and storage of TGs, 14 and SCD-1 catalyzes the synthesis of monounsaturated fatty acids. However, expression of these lipid uptake and adipogenesis genes was not significantly increased in the livers of mice that received Ad-PPARg, implying that PPARg-mediated adipogenic transformation of hepatocytes may not be of significance in this model. The other possible explanation is that this effect is shadowed by adipogenesis in WAT, which showed extended and higher lipogenesis gene expression favoring a robust adipogenic transformation. Indeed, because of the increase in 4 The increased fat mass suggests that decreased steatosis may be the consequence of diversion of fat storage from the liver to the adipose tissue promoted by direct stimulation of PPARg in adipocytes. The resultant lowering of intrahepatic fat is sufficient to prevent or revert steatohepatitis. 9, 15, 16 Modulation of steatosis and inflammation by PPARgregulated adipocytokines was studied. 17, 18 The link between PPAR-g and steatohepatitis was explored further by measuring the levels of adipocyte-derived cytokines (adipokines) such as adiponectin, TNF-a and IL-6. Increased plasma pro-inflammatory adipokines (TNF-a and IL-6) and reduced plasma anti-inflammatory adipokine (adiponectin) are common findings in NASH patients. [19] [20] [21] Adiponectin is secreted by adipocytes and is important in mediating fatty acid oxidation and decreasing hepatic lipid content. 22 Adipocyte-derived circulating IL-6 is associated with insulin resistance in humans 23 and impairs insulin signaling in hepatocytes. 24 TNF-a is another adipocyte-derived circulating factor that has been shown to regulate insulin sensitivity negatively. 25 Our data showed that PPARg inhibited the expression of TNF-a and IL-6 and stimulated the production of adiponectin in adipose tissue, indicating that the anti-steatohepatitis action of PPARg is also mediated through regulating adipokines. 26 Intrahepatic TNF-a and IL-6 are key inflammatory factors involved in the development of steatohepatitis. 6, 27 These pro-inflammatory regulators are mediated, at least in part, through oxidative stress. 27, 28 In this study, PPARg activation significantly suppressed oxidative stress and blunted TNF-a and IL-6 gene expression in liver. Thus, the anti-inflammatory effects of PPARg may be partly related to inhibition of hepatic lipoperoxide and reductions in the mRNA expression levels of these regulators, in keeping with studies in other injury models that have shown that PPARg activation reduces proinflammatory cytokine production and inflammation. 29 In summary, activation of PPARg in adipose tissue improves its ability to store lipids in peripheral tissues, thereby reducing lipotoxicity in liver ( Figure 6 ). This function involves activation of genes encoding molecules that promote a combination of lipid storage and lipogenesis such as aP2, CD36, LPL, FATP-1, SREBP-1 and SCD-1. Activation of these metabolic pathways cause body-wide lipid repartitioning by increasing the TG content of adipose tissue and lowering free fatty acids and TGs in blood circulation and in liver. 9, 30 In addition, PPARg alters the release of adipokines from fat, including suppressing TNF-a and IL-6 and inducing adiponectin, which have far-reaching metabolic effects in other tissues with functions of promoting insulin sensitivity and fatty acid b-oxidation in liver. Moreover, PPARg inhibited hepatic lipoperoxide and reduced proinflammatory cytokines production. As a result, hepatic steatosis is reduced and inflammation is blunted ( Figure  6 ). Notably, PPARg is necessary for therapeutic effectiveness of rosiglitazone through activation of this endogenous pathway. Introduction of PPARg by gene delivery combining with rosiglitazone had a markedly better effect on treatment of steatohepatitis. Information gained from this study may be clinically relevant for understanding the mechanisms and future treatment of NASH.
Materials and methods
Animals and treatments
PPARg
+/À mice were kindly supplied by Professor Frank J Gonzalez (Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA). The generation of the transgenic mice was described previously. 31 In brief, PPARg loxP-targeted/wild-type mouse (PPARg fl/+ ) was crossed with transgenic mice expressing Cre recombinase. Figure 6 Schematic diagram for the mechanisms of PPARg protection against nutritional steatohepatitis. PPARg is an important endogenous regulator and potential therapeutic target for dietary steatohepatitis. On the basis of our findings, it is proposed that PPARg is associated with several biological effects: (1) diversion of fat storage from the liver to the adipose tissue through promoting lipid storage (aP2, FATP-1, CD36 and LPL) and lipogenic genes (SREBP-1, SCD-1 and FAS) in adipose tissue; (2) mediation of the release of adipokines from fat (suppressing TNF-a and IL-6 and inducing adiponectin), which promotes insulin sensitivity and fatty acid oxidation in liver; and (3) inhibition of hepatic lipoperoxide and hepatic pro-inflammatory cytokines (TNF-a and IL-6) production.
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The targeted allele with loxP sites flanking exon 2 of the PPARg gene was deleted, generating PPARg +/À mice. PPARg +/À mice were bred to obtain PPARg +/À or wildtype mice with an offspring genotype distribution following the Mendelian frequency. Genotyping was performed using PCR as described previously. 32 Animals were housed in an air-conditioned room under a 12-h light/12-h dark cycle and allowed free access to food and water.
Experimental diets included the MCD diet (cat. no. 960439; ICN, Aurora, OH, USA), control diet (MCD diet supplemented with DL-methionine (3 g kg -1 ) and choline chloride (2 g kg -1 ), cat. no. 960441; ICN), and MCD diet supplemented with a selective PPARg ligand rosiglitazone 150 or 300 p.p.m. (GlaxoSmithKline, Research Triangle Park, NC, USA). At the end of treatments, blood was collected by cardiac puncture under anesthesia. Livers were rapidly excised and weighed. Aliquots were snap frozen in liquid nitrogen and kept at À80 1C until analyzed. A portion of each liver was fixed in 4% formalin for histology assessment. All experiments in this study were conducted in accordance with the guideline by the animal experimentation ethics committee of the Chinese University of Hong Kong.
Adenovirus-mediated gene transfer
Recombinant adenovirus containing the mouse PPARg1 complementary DNA (Ad-PPARg) under regulation of CMV promoter and recombinant adenovirus containing Escherichia coli b-galactosidase gene (Ad-LacZ) as control adenovirus vector were generous gifts from Dr JK Reddy (Department of Pathology, Northwestern University, the Feinberg School of Medicine, Chicago, IL, USA). Adenovirus was propagated, isolated in HEK293 cells and purified with Adeno-X Virus Purification kit (Clontech, Mountain View, CA, USA). Titer of the viral solution was determined by Adeno-X Rapid Titer kit (Clontech). The virus was stored at À80 1C until use. X-gal staining was used to indicate the gene transfer efficiency over the time of 1, 3, 5 and 7 days using X-gal Staining Assay Kit (Genlantis, San Diego, CA, USA). The extensive transduction was achieved at 3 and 5 days in the liver (Figure 3a ) at an amount of 2.5 Â 10 8 PFU. Mice were given intraperitoneal injection of Ad-PPARg or Ad-LacZ at an amount of 2.5 Â 10 8 PFU suspended in 100 ml phosphate-buffered saline every 4 days.
Biochemical assays
Serum ALT was determined using spectrophotometric assay kits (Sigma, St Louis, MO, USA). TG content in liver was determined by Triglyceride E-test kit (Wako Pure Chemical Industries, Osaka, Japan). Liver lipoperoxide level was estimated using the thiobarbituric acid-reactive substances assay with 1,1,3,3-tetramethoxypropane as a standard (Sigma).
Assessment of liver pathology
Formalin-fixed paraffin-embedded liver sections, 4 mm thick, were stained with hematoxylin and eosin. Liver histology was examined by two independent investigators and scored for hepatic steatosis (0, none; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100% hepatocytes affected) and inflammation (0, none; 1, mild; 2, moderate; and 3, severe) as described previously. 6 
Real-time quantitative PCR
Total RNA was extracted from liver and epididymal WAT using TRIzol (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed using 5 mg of total RNA with M-MLV Reverse Transcriptase (Promega, Madison, WI, USA). The complementary DNA was diluted 100-folds and 5 ml was used as a template per PCR reaction. Expression levels of aP2, FATP-1, CD36, LPL, acyl CoA synthase, SREBP-1, SCD-1, TNF-a, IL-6 and PPARg were determined by real-time PCR using SYBRGreen Master Mix (Applied Biosystems, Foster City, CA, USA). Level of b-actin mRNA was served as an internal control to normalize variations in complementary DNA contents. Primers are listed in Supplementary Table 1 .
Western blotting analysis
Total protein of WAT and liver was extracted by homogenizing tissue in Tris-HCl (pH 7.4) buffer containing a protease inhibitor cocktail (Roche, Indiapolis, IN, USA). A total of 30 mg of protein was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto equilibrated polyvinylidene difluoride membrane (Amersham Biosciences, Buckinghamshire, UK) by electroblotting. After incubation with primary and secondary antibody conjugated with horseradish peroxidase, proteins were detected by enhanced chemiluminescence (Amersham Biosciences). Individual level of target protein expression was normalized to b-actin (Cell Signaling Technology, Danvers, MA, USA).
Inflammatory cytokine assay
Hepatic inflammatory cytokine levels were detected using Bio-Plex Mouse cytokine assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). The amount of each cytokine was expressed relative to the protein amount of the liver lysate measured by the Bradford method (DC protein assay).
Statistics
Results are presented as mean±s.d. Statistical difference between two groups was analyzed using two-tailed Student's t-test. Statistical difference among more than two groups was analyzed using one-way ANOVA with Tukey post hoc comparison. A P-value of o0.05 was considered statistically significant.
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